Previous studies revealed increased serum concentrations of this anti-obesity hepatokine in individuals with metabolic syndrome and type 2 diabetes and decreased circulating ANGPTL6 levels in hemodialyzed individuals compared to healthy subjects [44,46,47]. This evidence concerns the gene ANGPTL6 and obesity disorder.